Prion diseases in humans: an update

ROB BUTLER

Summary  The year 2006 marks 20 years from the first identified bovine spongiform encephalitis in cows and 10 years from the first description of variant Creutzfeldt–Jakob disease in humans. The threatened epidemic in humans now appears unlikely, but psychiatrists need to be aware of recent developments in prion diseases.

Declaration of interest  None.

When the mass incineration of British cattle was a recent memory 5 years ago, cases of variant Creutzfeldt–Jakob disease (vCJD) were increasing each year and educating doctors about the disease was a priority. I co-reviewed the psychiatric management of CJD for Advances in Psychiatric Treatment (Butler & Fleminger, 2001). There were dire predictions about the impact of prion diseases for psychiatrists in the coming years. However, what happened since? What is the latest research? And what is the relevance of prion diseases for psychiatrists in the coming years?

THE THREATENED EPIDEMIC

From the first death in 1995 until the end of 2005, 153 people died from vCJD in the UK (http://www.cjd.ed.ac.uk). There have been about 18 cases of vCJD in France and 12 in the rest of the world. The families and loved ones of those who died have had to contend not only with the disease itself but with healthcare systems that were unprepared, often ignorant and unable to provide a coordinated response. Some of the families formed themselves into support groups such as the CJD Support Network and the Human BSE Foundation. They have lobbied for better services, greater awareness from health professionals and easier access to potential treatments. A trust has been established to pay compensation to the victims of vCJD and their families (http://www.cjdtrust.co.uk).

The number of deaths from vCJD in the UK appeared to peak in 2000 when 28 people died. Last year 5 people died. These numbers are surprisingly low in view of the millions of people who were exposed to infected beef products in the late 1980s. The transmission barrier may have been sufficient to prevent the feared epidemic. Deaths from sporadic CJD continue worldwide at about one per million people per year.

There have been some worrying developments. Cases have been identified in a number of countries around the world, and it is likely that people in more countries will be affected. Many were resident in the UK at some period, but others were probably exposed in their own country to indigenous bovine spongiform encephalitis (BSE) or imports from the UK.

There has been human to human transmission of vCJD via blood products. This comes with many ethical considerations, such as how to deal with those who were exposed to these blood products (Bird, 2004). There remains the risk of transmission by dura mater grafts, human pituitary hormones or surgical instruments because traditional sterilisation does not neutralise prions. Prion diseases are widespread in animals around the world, including scrapie in sheep, and are under-tested in some countries. Despite this, BSE has been detected in most European countries, USA, Canada and Japan.

CLINICAL FEATURES AND INVESTIGATIONS

Sporadic CJD peaks in incidence between 50 and 70 years of age. It is a rapidly progressive dementia, often with severe cerebellar and extrapyramidal signs and myoclonus, causing death usually within a few months (Will & Matthews, 1984). Psychiatric symptoms occur early in the disease in about a third of cases.

Variant CJD differs from sporadic CJD in a number of ways (Will et al, 1996); the National CJD Surveillance Unit published the clinical features of the first 100 cases of vCJD (Spencer et al, 2002). Onset is usually at a young age, mean 26 years, range 12 to 74 years. Patients tend to present to psychiatrists as first-line specialists, with early symptoms of dysphoria, withdrawal, anxiety, irritability, insomnia or loss of interest. Neurological symptoms occur on average 2 months later. These include pain, headaches, dropping things, sweating and loss of consciousness. The combination of a psychiatric disorder with affective or psychotic features, and persistent pain, dysarthria, gait ataxia, or sensory symptoms, should raise the suspicion of vCJD, particularly if there is a suggestion of cognitive impairment. Mean survival is a little over 1 year.
A number of investigations are useful. Electroencephalograms often show periodic synchronous discharges in CJD that are usually absent in vCJD. Computed tomography is usually normal or shows only atrophy. Magnetic resonance imaging may show a high signal in the posterior thalamus (pulvinar) in vCJD. In sporadic CJD, cerebrospinal fluid is usually positive for the brain protein 14-3-3 (which may be a marker for neuronal damage), but this test is not useful for vCJD. Tonsillar biopsy is used for diagnosing vCJD.

Most cases of sporadic CJD, and until recently all cases of vCJD, have been homozygous for methionine at codon 129 of the prion protein gene (the MM genotype found in around 40% of the general population). The announcement in 2004, that someone with vCJD infection (but not the illness) linked to a blood transfusion had the MV genotype (found in 50% of the general population) suggests this wider group of people may be at risk, perhaps with different incubation characteristics.

**WHAT TO DO IF YOU SUSPECT A PRION DISEASE**

A number of countries have established surveillance centres to monitor the occurrence of prion diseases. In the UK, psychiatrists who suspect that a patient has CJD should make a referral to the local neurological service which should contact the National CJD Surveillance Unit in Edinburgh. Their website (http://www.cjd.ed.ac.uk) includes information about managing CJD and addresses of support organisations. In the USA, doctors should contact the National Prion Disease Pathology Surveillance Center (http://www.cjdsurveillance.com).

It has been difficult to find treatments. In 2004, the Medical Research Council in the UK launched the PRION-1 trial that focuses initially on quinacrine, an antimarial that clears scrapie prion protein in cell culture. Pentosan polysulphate has shown promising results in animals. It has to be delivered directly to the brain. In a high-profile case, a father won a court battle to have pentosan polysulphate made available for his son. Attempts to find a vaccine for the abnormal prion protein are still an early stage. A better understanding of the mechanism of disease is offering novel treatment approaches, such as finding agents that directly target prion protein. For example, transgenes have reversed prion disease in mice by deleting prion protein genes (Mallucci & Collinge, 2004).

**CONCLUSIONS**

Most of what we wrote in Advances in Psychiatric Treatment is still relevant 5 years on, but prion diseases are better understood. Almost two-thirds of people with vCJD will see a psychiatrist at some stage of their illness (Spencer et al, 2002).

Psychiatrists need to know about prion diseases; they need to complete good clinical assessments, particularly in unusual cases; and they need to be responsive to this group of patients and their families. Fortunately, the worst predictions have not materialised, but it is too early to lower our awareness of this group of disorders.

**REFERENCES**


Prion diseases in humans: an update
ROB BUTLER
Access the most recent version at DOI: 10.1192/bjp.bp.106.021832

References
This article cites 9 articles, 6 of which you can access for free at:
http://bjp.rcpsych.org/content/189/4/295#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;189/4/295

Downloaded from
http://bjp.rcpsych.org/ on November 7, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/